4-Chloro-7-methoxy-1,6-naphthyridine, 95.0%, 250mg

2-Bromo-4-nitrobenzaldehyde, 95.0%, 1g

3-(Fluoromethyl)azetidin-3-ol hydrochloride, 97%, 100mg

3-Oxo-3-p-tolyl-propionic acid methyl ester, 95.0%, 1g

4,5,6,7-tetrahydro-2H-indazol-3-ol, 5g

3-((Tert-butoxycarbonyl)amino)-3-(4-(methylthio)phenyl)propanoic acid, 97%, 100mg

Azido-PEG4-CH2-Boc, 97%, 100mg

Nalpha-Carbobenzoxy-L-histidine>99.0%(T)1g

4-Fluoro-3-methylbenzoic acid, 97.0%, 1kg

(6-Bromo-5-fluoropyridin-3-yl)methanol, 98%, 1g

3-(Difluoromethyl)-3-methylazetidinehydrochloride, 97%, 100mg

E-Plan phase EPLPH 10x/0.25 objective. Working distance 6.61 mm

2-Bromobenzoyl Chloride>98.0%(GC)(T)250g